Ventyx Biosciences (NASDAQ:VTYX – Get Rating) released its quarterly earnings data on Thursday. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.07, MarketWatch Earnings reports.
VTYX traded up $0.38 on Friday, reaching $14.91. The company had a trading volume of 207,991 shares, compared to its average volume of 150,796. The business has a 50 day simple moving average of $13.44 and a 200 day simple moving average of $15.42. Ventyx Biosciences has a 52-week low of $9.50 and a 52-week high of $26.00.
Several analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Ventyx Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 26th. Oppenheimer assumed coverage on shares of Ventyx Biosciences in a research note on Tuesday, February 1st. They issued an “outperform” rating and a $30.00 target price for the company. Canaccord Genuity Group initiated coverage on shares of Ventyx Biosciences in a research note on Thursday, March 31st. They issued a “buy” rating for the company. Credit Suisse Group initiated coverage on shares of Ventyx Biosciences in a research report on Monday, May 9th. They set an “outperform” rating and a $53.00 price target for the company. Finally, Canaccord Genuity Group initiated coverage on shares of Ventyx Biosciences in a research report on Thursday, March 31st. They set a “buy” rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Ventyx Biosciences presently has an average rating of “Buy” and an average target price of $40.50.
About Ventyx Biosciences (Get Rating)
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus.
- Get a free copy of the StockNews.com research report on Ventyx Biosciences (VTYX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.